US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
You may also be interested in...
The disclosure requirement to participate includes an option for the US FDA to include the ideas on new regulatory uses for real-world evidence in a guidance or speak about them at public forums in order to ‘promote innovation.’
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
FDA Commissioner Hahn says industry needs to work with the agency to establish a link to more detailed supply chain information.